申请人:Kyorin Pharmaceutical Co., Ltd.
公开号:US07868183B2
公开(公告)日:2011-01-11
The industrial production of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutanamide, a urinary incontinence remedy, necessitates elimination of problems concerning the use of a synthetic adsorbent, e.g., HP-20, the efficiency of operation with the same, purification efficiency, etc. An acid salt, e.g., hydrochloride or phosphate, of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutanamide or a hydrate of any of these salts is used as an intermediate. This intermediate is neutralized and then purified. Thus, high-purity 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutanamide is easily obtained in satisfactory yield. The industrial-scale production process has been thus established.
4-(2-甲基-1-咪唑基)-2,2-二苯基丁酰胺是一种治疗尿失禁的药物,其工业生产需要解决使用合成吸附剂(例如HP-20)的问题,包括操作效率、纯化效率等。该药物的酸盐(例如盐酸盐或磷酸盐)或这些盐的水合物被用作中间体。该中间体被中和和纯化。因此,高纯度的4-(2-甲基-1-咪唑基)-2,2-二苯基丁酰胺可以轻松地获得,并且产率令人满意。工业规模的生产过程已经被建立。